What is Medicortex?
Founded in 2014, Medicortex is at the forefront of developing biomarker diagnostics for Traumatic Brain Injury (TBI). Their core mission is to create precise tools that evaluate the extent and severity of concussions and TBIs, aiming to revolutionize patient care and recovery pathways. The company's strategic focus on objective diagnostic markers positions it as a key player in the neurodiagnostics sector.
How much funding has Medicortex raised?
Medicortex has raised a total of $584K across 1 funding round:
Share Placement
$584K
Share Placement (2021): $584K, investors not publicly disclosed
What's next for Medicortex?
With its recent major strategic investment, Medicortex is poised for significant growth and expansion. This capital infusion is expected to accelerate the development and commercialization of their TBI biomarker diagnostics. The company's trajectory suggests a move towards scaling operations, potentially entering new markets, and further solidifying its position as a leader in neurotrauma diagnostics. Future developments will likely focus on clinical validation and broader market adoption of their innovative solutions.
See full Medicortex company page
